Abviva to receive patent for its new Mammastatin technology
Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer-related applications of Mammastatin, announced that the Canadian Patent Office issued notice that it will be issuing patent application Number 2.267.095 within 12 weeks
